Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Compass Therapeutics, Inc. (CMPX) is a Biotechnology company based in US with a market capitalization of $290.4M. Free cash flow was negative at -$49.2M. This page tracks CMPX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 35 employees · IPO Apr 5, 2021
Valuation
Valuation & price
$1.86as of May 17, 2026· -72.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.48
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$290.4M
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$49.2M
Free cash flow (USD)
-$199.1M
Net debt
Net cash position
15.0%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Value screen
Graham defensive-investor tests
2
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 5, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 1, 2026Filing
Corporate Presentation
- 8-K eventJun 22, 2026Filing
Bylaw Amendments
- 8-K eventJun 11, 2026Filing
Annual Meeting Results
- 8-K eventMay 5, 2026Filing
Earnings Release
- Quarterly reportMay 5, 2026Filing
10-Q Filed
- Insider buyApr 30, 2026Filing
Insider Buy $47KAnderman Jonathan · General Counsel · $47.3K
- Insider buyApr 30, 2026Filing
Insider Buy $28KLerner Neil · Chief Accounting Officer · $28.4K
- 8-K eventApr 27, 2026Filing
Clinical Trial Results Announced
Questions
Frequently asked questions
What is Compass Therapeutics, Inc.'s market cap?
Compass Therapeutics, Inc. (CMPX) has a market capitalization of $290.4M.
What is CMPX's P/E ratio?
A meaningful P/E ratio is not available for CMPX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is CMPX's price-to-book (P/B) ratio?
CMPX trades at 1.48 times book value per share.
Are insiders buying CMPX stock?
Yes — SEC Form 4 filings show 2 open-market insider buys and 0 sells at Compass Therapeutics, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.